Command Palette

Search for a command to run...

Preprint WatchMildOctober 29th, 2026

Dual Control of Low-Density Lipoprotein Cholesterol Levels by ANGPTL3 and ANGPTL8

Xu, Y.; Luo, F.; Fletcher, J.; Inigo, M. M.; Burgess, S.; Liang, G.; Kinch, L. N.; Kozlitina, J.; Cohen, J. C.; Hobbs, H.

ANGPTL3 circulates as full-length, N-terminal and C-terminal fragments, and LDL cholesterol control is exerted jointly with ANGPTL8, so the optimal way to inactivate ANGPTL3 depends on which circulating form is neutralised.

Mild contradiction

1 prior failure

One documented clinical failure (Phase 1 or 2) overlaps with the claimed mechanism.

The ANGPTL3 entry in Claidex is zodasiran (ARO-ANG3) in homozygous familial hypercholesterolemia, a Phase 2 shut down on sponsor grounds (aro-ang3-zodasiran-hofh-phase2-strategic-shutdown). This preprint states directly that the best approach to inactivating ANGPTL3 remains unclear and that the contribution of each circulating fragment differs, which is a live question for any modality choice between RNA interference, antibody and small molecule. Knockdown of the whole transcript and neutralisation of a single fragment are not interchangeable interventions. A program picking a modality here should say which ANGPTL3 species it intends to remove and what LDL cholesterol effect it attributes to that species.

Abstract excerpt

BACKGROUND: Inactivation of ANGPTL3 (angiopoietin-like protein 3, A3) is a proven therapeutic strategy for lowering plasma lipid levels independently of the LDL receptor (LDLR), yet the optimal approach to inactivate A3 remains unclear. A3 is proteolytically cleaved and circulates as full-length (A3-FL), N-terminal (A3-Nter) and C-terminal (A3-Cter) fragments. The specific contribution of each form of A3, and of its paralog, ANGPTL8 (A8), in modulating circulating levels of ApoB-Containing Lipoproteins (ABCLs) remain poorly defined. Clarifying these relationships will inform next-generation A3-directed therapies. METHODS: We performed liver perfusion studies to directly compare the number and composition of VLDL particles secreted from mice with and without A3. To amplify effects on cholesterol metabolism, we generated Ldlr-/- mice expressing wildtype A3 (A3-WT), A3-FL or A3-Nter, with or without co-expression of A8, and analyzed plasma lipids, circulating A3 and A8 complexes, and intravascular lipase activities. Complementary in vitro assays and structural modeling were used to assess relative endothelial lipase (EL) inhibition by A3 alone or in complex with A8. RESULTS: Liver perfusion studies revealed that A3 inactivation does not alter the rates of hepatic secretion of VLDL in wildtype or Ldlr-/- mice. Inactivation of A8 alone lowered plasma LDL-cholesterol (C) levels by ~20%, an effect dependent upon the expression of both EL and A3. Maximal inhibition of lipoprotein lipase (LPL) required co-expression of A8 plus both A3-FL and A3-Nter, indicating that A3 cleavage, in addition to A8 expression, is essential for maximal LPL inhibition. In contrast, A8 expression, but not A3 cleavage, was required for optimal EL inhibition. CONCLUSIONS: A8 acts in concert with A3 to differentially modulate LPL- and EL-mediated lipolysis, which antagonizes hepatic clearance of newly-secreted atherogenic ABCLs. This mechanistic framework refines our understanding of A3-targeted lipid lowering and highlights the therapeutic potential of dual A3- plus A8-directed strategies to treat dyslipidemia and prevent atherosclerotic cardiovascular disease.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.